Datasheet

Version: 2.0.0 Revision date: 03 Dec 2024



Human Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) CLIA Kit

Catalogue No.:abx492046

Human Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) Chemiluminescent Immunoassay (CLIA) Kit is a Sandwich Chemiluminescent Immunoassay (CLIA) Kit for use with Tissue homogenates, cell lysates and other biological fluids.

Target: Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A)

Reactivity: Human

Tested Applications: CLIA

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Storage: Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

Validity: The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.

Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within

the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested

that the whole assay is performed by the same user throughout.

UniProt Primary AC: P42771 (UniProt, ExPASy)

Gene Symbol: CDKN2A

GenelD: 1029

OMIM: 600160 155601

HGNC: 1787

KEGG: hsa:1029

Ensembl: ENSG00000147889

Test Range: 0.625 ng/ml - 40 ng/ml

Sensitivity: < 0.232 ng/ml

Standard Form: Lyophilized

Datasheet

Version: 2.0.0 Revision date: 03 Dec 2024



Detection Method: Chemiluminescent

Assay Type: Sandwich

Assay Data: Quantitative

Sample Type: Tissue homogenates, cell lysates and other biological fluids.

Note: This product is for research use only.

The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.

Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

